



UCCH Pathway

UCCH Guideline Malignant Melanoma

2.03.01 Anlage 18

Version September/2022

Guideline Malignant Melanoma

Version 3.3 Juli 2020 (AWMF-Reg. Nummer 032/024O)

TNM classification of the AJCC 2017 (8th edition)

Malignant Melanoma board members

C. Gebhardt, T. Haalck, M. Christolouka, N. Booken, L. Hildebrandt, S.W. Schneider (Dermatology)

M. Fischer (Dermatology, BWK)

W. Fiedler (Med. Oncology)

A. Krüll (Radiooncology)

U. Goebel (patient representative UCCH)

Responsible author C. Gebhardt (Dermatology)

Implemented Apr/2008

Revised May/2012, May/2014, May/2016, May/2018, July/2020, Sep/2022

Next planned review Sep/2024

Legend of Colours



= Therapeutic procedure



= Clinical or diagnostic condition



= Diagnostic procedure



= Clinical trial



= Supportive measure



= Referral



=Tumorboard (including post tumorboard interaction with patient that follows the principles of shared decision-making)

Tumorboard Decision is required for the Following Situations:

- Every Case of Melanoma from Stage IIC and higher (AJCC v8)
- First Diagnosis or Progression of Metastatic Melanoma

Suspicious pigmented lesion

Excisional biopsy with 0,1 – 0,5 cm margin

Work up

(In case of confirmed melanoma)

• **Pathology report:**

- Maximum tumor (Breslow) thickness
- Ulceration status
- Mitotic rate (though not required for staging according to AJCC 2017 (8th edition))
- Deep and peripheral margin status
- Primaries >4,0mm tumor thickness (Breslow) or all metastases:

Mutation Analysis (BRAF, NRAS: all; cKIT: e.g. mucosal or acral melanoma; GNAQ, GNA11: e.g. uveal melanoma; NTRK fusions: 2nd line) and PD-L1 Status; Microsatellitosis

- Optional: level of invasion, angiolymphatic invasion, histologic subtype, regression, tumor-infiltrating lymphocytes

- Complete clinical **skin examination** with attention to locoregional area and draining nodes
- Assessment of melanoma **risk factors**¹
- Offer **psychooncological support**
- Offer **self help group support**

Stage 0 in situ

Pathway page 2

Stage IA

Pathway page 2

Stage IB
Stage II

Pathway page 2

Stage III
Positive nodes

Pathway page 3

Stage III
In transit


Pathway page 3

Stage IV
Distant metastases

Pathway page 4

¹ Melanoma risk factors: family history, prior primary melanoma, atypical moles, UV exposure

Pathway page 2: Primary Therapy Stage 0-IIC



² Recommended 0 cm (S3 guideline) but 0,5 cm margin may be considered


³ Consider SLNB in stage IA if pT1a with adverse features (eg, high mitotic rate, regression) or young age (<40 years) or pT1b (AJCC 8th ed.)

⁴ Recommended safety distance in relation to tumor size according to Breslow thickness: ≥ 1 mm - <2 mm: 1 cm, ≥ 2 mm: 2 cm


⁵ Recommended only in tumor stage IIC

⁶ Pembrolizumab recommended only in tumor stages IIB+IIC


Pathway page 3: Primary Therapy Stage III A/B/C/D




Pathway page 4: Primary Therapy Stage IV



Pathway page 5: Recurrence



Page 6: Follow up



⁶ After curative treatment